Search Results

Dermavant Sciences has received approval in Japan for tapinarof cream, 1% for the treatment of both adults with psoriasis and patients 12 years of age and older with atopic dermatitis.

The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.

Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.

Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.

Dermavant Sciences today announced the appointment of John Darden as Vice President of Marketing. Darden brings more than 15 years of sales, marketing and market access experience in dermatology and immunology.

Dermavant Sciences today announced that the data from ADORING 1 and ADORING 2, two identical, double-blind, randomized, vehicle-controlled pivotal Phase 3 trials of VTAMA® (tapinarof) cream, 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology.

Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA® (tapinarof) cream.